Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Aimovig “Wear-Off”: A Retrospective Case Series of Response to 14 day Dosing
Headache
P4 - Poster Session 4 (5:30 PM-6:30 PM)
7-002
The primary objective of this study was to identify if changing dosing in patients taking Aimovig 140mg with“wear-off” effect, to 70mg injections every 14 days would decrease monthly headache frequency and/or severity.
As demonstrated in collaborative research, a small cohort of patients on Aimovig 140mg once monthly injections have been found to have a “wear-off” effect where the medication was found to be not as effective by the end of the month as it was at the beginning of the month.

Through retrospective chart review, we identified patients that were started on Aimovig 140mg monthly injections that had, response to medication with reduction in headache frequency and severity >50% for the first 2-3 months followed by a "wear-off" effect. Patients were offered a change in dosing to Aimovig 70mg to be taken every 14 days. Response to change in dosing was measured per patient report in respect to frequency and severity at next clinical visit or by phone call interview.
17 patients were identified as having a “wear-off” effect. Of these 17 patients, 6 opted to switch to every 14 day dosing. By study start date, 5 of these 6 patients had been seen for follow up or had been contacted for phone interview. Three patients (60%) had a reduction in both headache frequency and severity. One patient (10%) had a reduction in severity alone. One patient (10%) had no change in monthly headache frequency or severity. Side effects were noted to be increased constipation in one patient (10%), injection site reaction one patient (10%), and vertigo when supine in one patient (10%). 
For patients with Aimovig “Wear-Off”, switching therapy from Aimovig 140mg single monthly injections to 70mg injections every 14 days is an option that can potentially reduce monthly headache frequency and severity, while maintaining mild side effect profile.
Authors/Disclosures
Naveen George, DO
PRESENTER 		Dr. George has nothing to disclose.
Daniel I. Feldman, MD (Cleveland Clinic Foundation) No disclosure on file
Deborah Reed, MD (Uhc) No disclosure on file